Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹2 Cr
Revenue (TTM)
₹197 Cr
Net Profit (TTM)
₹23 Cr
ROE
62.7 %
ROCE
25.2 %
P/E Ratio
0.1
P/B Ratio
-0.1
Industry P/E
--
EV/EBITDA
27
Div. Yield
0 %
Debt to Equity
2.5
Book Value
₹19532.4
EPS
₹9271.6
Face value
2
Shares outstanding
5,755,625
CFO
₹88.10 Cr
EBITDA
₹-352.70 Cr
Net Profit
₹-731.77 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sharon Bio-Medicine
| -34.7 | -4.3 | -34.7 | -42.1 | -34.4 | -39.9 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
BSE Healthcare#
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2018
|
2017
|
2016
|
2015
|
2014
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
| -29.4 | -21.0 | -66.8 | -25.2 | -14.2 |
|
BSE Sensex
| 5.9 | 27.9 | 1.9 | -5.0 | 29.9 |
|
BSE Healthcare
| -5.9 | 0.5 | -12.9 | 15.1 | 47.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
3.3 | 1.9 | 197.5 | 23.2 | 7.5 | 62.7 | 0.1 | -0.1 |
| 2,110.2 | 17,282.6 | 1,215.1 | 284.8 | 28.7 | 21.1 | 60.2 | 11.4 | |
| 656.2 | 12,893.6 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.5 | 2.4 | |
| 613.6 | 15,214.7 | 5,092.5 | 545.5 | 15.9 | 14.1 | 27.9 | 3.7 | |
| 839.3 | 13,375.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 30.9 | 2.0 | |
| 1,027.6 | 18,409.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.8 | 2.1 | |
| 1,404.5 | 16,092.2 | 1,419.3 | 20.1 | 8.4 | 0.5 | 800.5 | 2.8 | |
| 142.2 | 18,882.0 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 391.1 | 15,752.9 | 3,720.2 | 352.1 | 13.7 | 8.2 | 44.7 | 3.3 | |
| 1,271.5 | 20,670.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 939.6 | 4.5 |
2 min read•By Vikas Vardhan
Manufacture of allopathic pharmaceutical preparations
Incorporated
1989
Chairman
--
Managing Director
--
Headquarters
Raigad, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Sharon Bio-Medicine Ltd is ₹3.30 (NSE) and ₹3.21 (BSE) as of 28-Mar-2019 IST. Sharon Bio-Medicine Ltd has given a return of -34.42% in the last 3 years.
The P/E ratio of Sharon Bio-Medicine Ltd is 0.10 times as on 28-Mar-2019.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
0.00
|
|
2024
|
0.00
|
0.00
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2017
|
0.00
|
-0.17
|
The 52-week high and low of Sharon Bio-Medicine Ltd are Rs -- and Rs -- as of 05-Apr-2026.
Sharon Bio-Medicine Ltd has a market capitalisation of ₹ 2 Cr as on 28-Mar-2019. As per SEBI classification, it is a company.
Before investing in Sharon Bio-Medicine Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-0.15
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.